Table 2.
Recent exposure to antibiotics in VRE-positive and VRE-negative participants
| Antibiotics | No. (%) with VRE status: |
Odds ratio (95% CI) | P | |
|---|---|---|---|---|
| Positive | Negative | |||
| n | 13 | 90 | ||
| Penicillins | 3 (23.1) | 9 (10.0) | 2.7 (0.5–11.4) | 0.1 |
| Cephalosporins | 1 (7.7) | 6 (6.7) | 1.2 (0.1–8.8) | 0.8 |
| Trimethoprim | 1 (7.7) | 2 (2.2) | 3.7 (0.1–50.4) | 0.2 |
| Trimethoprim-sulfamethoxazole | 3 (23.1) | 9 (10.0) | 2.7 (0.5–11.4) | 0.1 |
| Amoxicillin-clavulanic acid | 2 (15.4) | 1 (1.1) | 16.2 (1.1–481.2) | 0.021 |
| Piperacillin-tazobactam | 3 (23.1) | 0 (0.0) | 0.007 | |
| Glycopeptides | 4 (30.7) | 1 (1.1) | 39.6 (4.1–985.5) | <0.001 |
| Macrolides | 2 (15.4) | 7 (7.7) | 2.2 (0.3–11.1) | 0.2 |
| Meropenem | 2 (15.4) | 0 (0.0) | 0.007 | |
| Aminoglycosides | 2 (15.4) | 1 (1.1) | 16.2 (1.1–481.2) | 0.021 |
| Tetracyclines | 0 (0.0) | 1 (1.1) | 0.6 | |
| Fluoroquinolones | 2 (15.4) | 1 (1.1) | 16.2 (1.1–481.2) | 0.021 |
| Fosfomycin | 1 (1.1) | 0 (0.0) | 0.6 | |